PMID: 11907185Mar 22, 2002Paper

Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys

The Journal of Pharmacology and Experimental Therapeutics
Alvin V TerryFrédérique Menzaghi

Abstract

Nicotine, a nonselective ligand for nicotinic acetylcholine receptors (nAChRs), has been shown to improve attention and reduce distractibility in humans. Although the numerous side effects induced by nicotine prevent its use as a therapeutic agent, it is hypothesized that subtype-selective nAChR ligands may offer a potential therapeutic benefit to humans with attention deficits. In this study, we evaluated the attention-enhancing properties of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a ligand selective for neuronal nAChRs with predominant activity at the human beta 4 subtype. SIB-1553A was evaluated in a test of attention (i.e., five-choice serial reaction time task or SRTT) and distractibility (i.e., delayed matching to sample task with distractor or DMTS-D) in adult rats and monkeys, respectively. SIB-1553A did not improve SRTT performance in normal rats, but reversed deficits induced by the N-methyl-D-aspartate (NMDA) antagonist dizocilpine. In the DMTS-D, SIB-1553A improved accuracy across several doses at the short delay intervals, which were affected most by distracting stimuli in adult monkeys. Subsequent testing with optimal doses for each monkey was also associated with signific...Continue Reading

References

Jun 14, 1991·Brain Research·E AizenmanI J Reynolds
Jan 1, 1985·Annals of the New York Academy of Sciences·A F Arnsten, P S Goldman-Rakic
Jun 30, 1994·Behavioural Brain Research·H Dai, R J Carey
Aug 1, 1994·Pharmacology, Biochemistry, and Behavior·E A BuffaloM G Paule
Aug 1, 1993·Pharmacology, Biochemistry, and Behavior·A V TerryW J Jackson
Jan 1, 1995·Alzheimer Disease and Associated Disorders·A D Lawrence, B J Sahakian
Jan 1, 1996·Psychopharmacology·E D LevinJ March
Apr 1, 1996·Journal of the American Academy of Child and Adolescent Psychiatry·T SpencerS Griffin
Sep 2, 1998·Psychopharmacology·E D Levin, B B Simon
Jan 8, 1999·The New England Journal of Medicine·A J Zametkin, M Ernst
Jan 29, 1999·Methods and Findings in Experimental and Clinical Pharmacology·M B Passani, P Blandina
Mar 11, 1999·The New England Journal of Medicine·J EliaJ L Rapoport
Apr 20, 2000·European Journal of Pharmacology·I P StolermanM Shoaib
Mar 7, 2001·Biological Psychiatry·A H Rezvani, E D Levin
Nov 2, 2001·Brain Research. Cognitive Brain Research·A M HimmelheberJ P Bruno

❮ Previous
Next ❯

Citations

Apr 28, 2004·Psychopharmacology·Simon N KatnerMichael A Taffe
Jun 5, 2013·Biochemical Pharmacology·Anshul A Pandya, Jerrel L Yakel
Aug 10, 2013·Biochemical Pharmacology·Edward D Levin
Nov 1, 2003·Pharmacology, Biochemistry, and Behavior·Joseph O'NeillL Jaime Fitten
Jun 4, 2005·Physiology & Behavior·Craig J Slawecki, Jennifer Roth
Jun 11, 2005·Trends in Pharmacological Sciences·Jerry J BuccafuscoPatrick M Lippiello
Apr 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A JacksonT Duka
Oct 15, 2013·Cellular and Molecular Life Sciences : CMLS·Eliane ProulxEvelyn K Lambe
Jun 10, 2005·Neuron·Angela J Yu, Peter Dayan
Feb 19, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jared W YoungJohn Sharkey
Nov 16, 2016·PLoS Biology·Louise MarshallSven Bestmann
Oct 28, 2006·The European Journal of Neuroscience·E Decamp, J S Schneider
Oct 9, 2015·The Journal of Pharmacology and Experimental Therapeutics·Henry S LangeJason M Uslaner
Feb 9, 2017·Journal of Psychopharmacology·Agnieszka PotasiewiczPiotr Popik
Apr 23, 2008·Current Protocols in Neuroscience·Susan B Powell, Mark A Geyer
Mar 23, 2011·Pharmacology, Biochemistry, and Behavior·Segev Barak, Ina Weiner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.